QQ客服 官方微博 反馈留言

浏览/检索结果: 共5条，第1-5条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择发表日期升序发表日期降序提交时间升序提交时间降序题名升序题名降序作者升序作者降序 Detachable Liposomes Combined Immunochemotherapy for Enhanced Triple-Negative Breast Cancer Treatment through Reprogramming of Tumor-Associated Macrophages 期刊论文 NANO LETTERS, 2021, 卷号: 21, 期号: 14, 页码: 6031-6041 作者:  Chen, Mingshu;  Miao, Yunqiu;  Qian, Kun;  Zhou, Xin;  Guo, Linmiao 收藏  |  浏览/下载：28/0  |  提交时间：2021/11/04 Immunochemotherapy  triple-negative breast cancer  liposomes  tumor-associated macrophages  MMP2 response   Clinical features, treatment and risk factors for interstitial pneumonia in B-cell non-Hodgkin lymphoma patients 期刊论文 TRANSLATIONAL CANCER RESEARCH, 2020, 卷号: 9 作者:  Li, Cong;  Lu, Fangxiao;  Lei, Tao;  Yu, Haifeng;  Yang, Haiyan 收藏  |  浏览/下载：22/0  |  提交时间：2020/11/30 B-cell lymphoma  chemotherapy  interstitial pneumonia (IP)  risk factor  rituximab   Enzyme responsiveness enhances the specificity and effectiveness of nanoparticles for the treatment of B16F10 melanoma 期刊论文 Journal of Controlled Release, 2019, 卷号: 316, 页码: 208-222 作者:  Huang, Yi;  Shi, Yanbin;  Wang, Qingjie;  Qi, Tongtong;  Fu, Xianglei 收藏  |  浏览/下载：42/0  |  提交时间：2019/12/11 Charge turnover  Combined immunochemotherapy  Enzyme responsiveness  Size shrinking   Nanotechnology-mediated immunochemotherapy combined with docetaxel and PD-L1 antibody increase therapeutic effects and decrease systemic toxicity 期刊论文 JOURNAL OF CONTROLLED RELEASE, 2018, 卷号: 286, 页码: 369-380 作者:  Gu, Zili;  Wang, Qingjie;  Shi, Yanbin;  Huang, Yi;  Zhang, Jing 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/11 Nanotechnology  Liposome  Docetaxel  PD-L1  Immunochemotherapy   Nanotechnology-mediated immunochemotherapy combined with docetaxel and PD-L1 antibody increase therapeutic effects and decrease systemic toxicity 期刊论文 JOURNAL OF CONTROLLED RELEASE, 2018, 卷号: Vol.286, 页码: 369-380 作者:  Gu, Zili;  Wang, Qingjie;  Shi, Yanbin;  Huang, Yi;  Zhang, Jing 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/26 Nanotechnology  Liposome  Docetaxel  PD-L1  Immunochemotherapy